Role of Macrophage Migration Inhibitory Factor (MIF) in Heart Failure
NCT ID: NCT03232671
Last Updated: 2022-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
180 participants
OBSERVATIONAL
2016-03-31
2020-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Clinical Diagnosis Meaning of MIF in Coronary Heart Disease
NCT01750502
Metabolic Substrate of Patients With Myocardial Infarction With and Without Modifiable Cardiovascular Risk Factors
NCT05494151
Multi-Center Evaluation of Feasibility of SPECT Measurement of Myocardial Blood Flow and Reserve
NCT03427749
WISE CVD - Continuation (WISE HFpEF)
NCT02582021
Cadmium-zinc-telluride (CZT) Imaging of Myocardial Blood Flow (MBF) (SPECT MBF)
NCT02280941
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MIF ELISA
Blood sample
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients fulfilling criteria for the diagnosis of HFrEF
* Patients fulfilling criteria for the diagnosis of HFpEF
* Patients fulfilling criteria for the diagnosis of HFmrEF
* Patients presenting with dyspnea according to the NYHA classification I-IV, elevated BNP/NT-proBNP levels and echocardiographic findings of heart failure.
Exclusion Criteria
* Patients with symptoms of heart failure without fulfilling the criteria of the ESC guidelines 2016
* Denial to participate
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Essen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fadi Al-Rashid
Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Lüdike, M.D.
Role: PRINCIPAL_INVESTIGATOR
University Hospital of Essen, Department of Cardiology and Vascular medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Essen
Essen, North Rhine-Westphalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Luedike P, Alatzides G, Papathanasiou M, Heisler M, Pohl J, Lehmann N, Rassaf T. Predictive potential of macrophage migration inhibitory factor (MIF) in patients with heart failure with preserved ejection fraction (HFpEF). Eur J Med Res. 2018 May 4;23(1):22. doi: 10.1186/s40001-018-0321-1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-6529-BO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.